“A significant majority of lung cancer patients experience a cough at some point during their cancer journey, which severely impacts their quality of life during an already challenging period. Despite its prevalence and impact, lung cancer cough is largely overlooked as a therapeutic target. Currently, no companies are actively developing specific treatments for lung cancer … Read more
Investor News
The issued share capital of Biovara has been increased to 8 million ordinary shares.
Biovara commissioned London-based independent research firm ACF Research to produce a thematic note delineating the lung cancer cough market. This is a significant subsegment of the overall cough market and the focus of Biovara’s business. Download the report here
Biovara is a young fast-growing company. We decided from the outset that ESG (Environment Social Governance) considerations would be at the heart of everything we do. We understand that there is a maturity curve in ESG policy which is why we are committed to the continual development of our own aims and processes. We … Read more
Oxilio is a pioneering pharmaceutical drug development company working to identify, repurpose and commercialise existing drugs to address unmet needs in cancer therapy – rapidly and cost effectively.